Kidney cancer, also known as renal cell cancer, begins in the kidneys and is common among adults and children (many children develop a specific kind of kidney cancer called Wilms' tumor). Risk of developing kidney cancer increases with age, smoking, being male, obesity, hypertension, exposure to chemicals, von hippel-lindau disease, treatment for kidney failure, and family history. Kidney cancer is most commonly treated with surgery, cryoablation, radiofrequency ablation, drug therapy, radiation therapy, and targeted therapy. In metastatic renal cell cancer, the cancer has spread to other organs such as lymph nodes, the lungs, liver, bones, or the brain. An estimated 70% of patients will develop metastases throughout their disease. This is not a good prognosis as survival rates of 5 years is about 5-15%. Survival rates are improved if surgery to remove all visible disease is performed. Radiation and chemotherapy are not typically used in metastatic renal cell cancer, but may be used in various situations.
Metastatic Renal Cell Cancer Bioinformatics Tool
Laverne is a handy bioinformatics tool to help facilitate scientific exploration of related genes, diseases and pathways based on co-citations. Explore more on Metastatic Renal Cell Cancer below!
For more information on how to use Laverne, please read the How to Guide.
We have 2792 products for the study of Metastatic Renal Cell Cancer that can be applied to Western Blot, Chromatin Immunoprecipitation, Flow Cytometry, Immunohistochemistry, Immunocytochemistry/Immunofluorescence from our catalog of antibodies and ELISA kits.
Metastatic Renal Cell Cancer is also known as Metastatic Kidney Cancer, Metastatic Renal Cell Carcinoma, Renal Cell Carcinoma Metastatic, Renal Cell Carcinoma, Metastatic.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.